Sodium-glucose cotransporter 2 inhibitors for type 2 diabetes: A systematic review and meta-analysis

Annals of Internal Medicine

Volumn 159, Issue 4, 2013, Pages 262-274

  Vasilakou, Despoina ^a   Karagiannis, Thomas ^a   Athanasiadou, Eleni ^a   Mainou, Maria ^a   Liakos, Aris ^a   Bekiari, Eleni ^a   Sarigianni, Maria ^a   Matthews, David R ^b   Tsapas, Apostolos ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; CANAGLIFLOZIN; DAPAGLIFLOZIN; EMPAGLIFLOZIN; ERTUGLIFLOZIN; HEMOGLOBIN A1C; INSULIN; IPRAGLIFLOZIN; LUSEOGLIFLOZIN; METFORMIN; PLACEBO; REMOGLIFLOZIN ETABONATE; SITAGLIPTIN; SODIUM GLUCOSE COTRANSPORTER 2; SODIUM GLUCOSE COTRANSPORTER 2 INHIBITOR; SULFONYLUREA; TOFOGLIFLOZIN; UNCLASSIFIED DRUG;

BLADDER CANCER; BODY WEIGHT; BREAST CANCER; DIASTOLIC BLOOD PRESSURE; DRUG EFFICACY; DRUG SAFETY; GENITAL TRACT INFECTION; HUMAN; HYPOGLYCEMIA; HYPOTENSION; INSULIN TREATMENT; META ANALYSIS; MONOTHERAPY; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW; SYSTEMATIC REVIEW; SYSTOLIC BLOOD PRESSURE; URINARY TRACT INFECTION;

BLOOD PRESSURE; DIABETES MELLITUS, TYPE 2; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; RISK ASSESSMENT; SELECTION BIAS; SODIUM-GLUCOSE TRANSPORTER 2; WEIGHT LOSS;

EID: 84882251091     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/0003-4819-159-4-201308200-00007     Document Type: Review

References (79)

1. Ferrannini E, Solini A. SGLT2 inhibition in diabetes mellitus: rationale and clinical prospects. Nat Rev Endocrinol. 2012;8:495-502. [PMID: 22310849]
2. Rahmoune H, Thompson PW, Ward JM, Smith CD, Hong G, Brown J. Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes. Diabetes. 2005;54:3427-34. [PMID: 16306358]
3. Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, et al; American Diabetes Association (ADA). Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-79. [PMID: 22517736]
4. U.S. Food and Drug Administration. FDA Briefing Document. NDA 202293. Dapagliflozin Tablets, 5 and 10 mg. Rockville, MD: U.S. Food and Drug Administration; 2011. Accessed at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/drugs/EndocrinologicandMetabolic DrugsAdvisoryCommittee/ucm262994.pdf on 1 April 2013.
5. Burki TK. FDA rejects novel diabetes drug over safety fears. Lancet. 2012; 379:507. [PMID: 22334883]
6. European Medicines Agency. Assessment Report: Forxiga (Dapagliflozin). Procedure no. EMEA/H/C/002322. London: European Medicines Agency; 2012. Accessed at www.ema.europa.eu/docs/en_GB/document_library/EPAR _-_Public_assessment_report/human/002322/WC500136024.pdf on 1 April 2013.
7. U.S. Food and Drug Administration. FDA Briefing Document. NDA 204042. Invokana (Canagliflozin) Tablets. Rockville, MD: U.S. Food and Drug Administration; 2013. Accessed at www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/EndocrinologicandMetabolicDrugs AdvisoryCommittee/UCM334550.pdf on 24 January 2013.
8. U.S. Food and Drug Administration. FDA approves Invokana to treat type 2 diabetes [news release]. Rockville, MD: U.S. Food and Drug Administration; 29 March 2013. Accessed at www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm345848.htm on 1 April 2013.
9. Clar C, Gill JA, Court R, Waugh N. Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes. BMJ Open. 2012;2. [PMID: 23087012]
10. Musso G, Gambino R, Cassader M, Pagano G. A novel approach to control hyperglycemia in type 2 diabetes: sodium glucose co-transport (SGLT) inhibitors: systematic review and meta-analysis of randomized trials. Ann Med. 2012;44: 375-93. [PMID: 21495788]
11. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med. 2009;151:W65-94. [PMID: 19622512]
12. Scottish Intercollegiate Guidelines Network. Search Filters. Edinburgh, United Kingdom: Scottish Intercollegiate Guidelines Network; 2013. Accessed at www.sign.ac.uk/methodology/filters.html on 8 January 2013.
13. Lefebvre C, Manheimer E, Glanville J. Searching for studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0. The Cochrane Collaboration; 2011.
14. Higgins JP, Altman DG, Gøtzsche PC, Jüni P, Moher D, Oxman AD, et al; Cochrane Bias Methods Group. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928. [PMID: 22008217]
15. Egger M, Davey Smith G, Schneider M, Minder C. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315:629-34. [PMID: 9310563]
16. Guyatt G, Oxman AD, Akl EA, Kunz R, Vist G, Brozek J, et al. GRADE guidelines: 1. Introduction-GRADE evidence profiles and summary of findings tables. J Clin Epidemiol. 2011;64:383-94. [PMID: 21195583]
17. Guyatt GH, Oxman AD, Kunz R, Woodcock J, Brozek J, Helfand M, et al; GRADE Working Group. GRADE guidelines: 7. Rating the quality of evidence-inconsistency. J Clin Epidemiol. 2011;64:1294-302. [PMID: 21803546]
18. Diamond GA, Bax L, Kaul S. Uncertain effects of rosiglitazone on the risk for myocardial infarction and cardiovascular death. Ann Intern Med. 2007;147: 578-81. [PMID: 17679700]
19. Review Manager (RevMan) [computer program]. Version 5.2. Copenhagen, Denmark: Nordic Cochrane Center, Cochrane Collaboration; 2012.
20. Bailey CJ, Iqbal N, T'joen C, List JF. Dapagliflozin monotherapy in drugnaïve patients with diabetes: a randomized-controlled trial of low-dose range. Diabetes Obes Metab. 2012;14:951-9. [PMID: 22776824]
21. Ferrannini E, Ramos SJ, Salsali A, Tang W, List JF. Dapagliflozin monotherapy in type 2 diabetic patients with inadequate glycemic control by diet and exercise: a randomized, double-blind, placebo-controlled, phase 3 trial. Diabetes Care. 2010;33:2217-24. [PMID: 20566676]
22. Woo V, Tang W, Salsali A, List FJ. Long-term efficacy of dapagliflozin monotherapy in patients with type 2 diabetes mellitus. Presented at International Diabetes Federation 21st World Diabetes Congress, Dubai, United Arab Emirates, 4-8 December 2011.
23. Ferrannini E, Seman L, Seewaldt-Becker E, Hantel S, Pinnetti S, Woerle HJ. A phase IIb, randomized, placebo-controlled study of the SGLT2 inhibitor empagliflozin in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15: 721-8. [PMID: 23398530]
24. Woerle HJ, Ferrannini E, Berk A, Manun'ebo M, Pinnetti S, Broedl UC. Safety and efficacy of empagliflozin as monotherapy or add-on to metformin in a 78-week open-label extension study in patients with type 2 diabetes [Abstract]. Diabetes. 2012;61(Suppl 1A):LB13.
25. Fonseca VA, Ferrannini E, Wilding JP, Wilpshaar W, Dhanjal P, Ball G, et al. Active-and placebo-controlled dose-finding study to assess the efficacy, safety, and tolerability of multiple doses of ipragliflozin in patients with type 2 diabetes mellitus. J Diabetes Complications. 2013;27:268-73. [PMID: 23276620]
26. Inagaki N, Kondo N, Iwasaki T, Maruyama N, Susuta Y, Sakai M, et al. Canagliflozin, a novel inhibitor of sodium glucose co-transporter 2 (SGLT2) improves glycemic control and reduces body weight in Japanese type 2 diabetes mellitus (T2DM) [Abstract]. Diabetes. 2011;60(Suppl 1):A274.
27. Kaku K, Inoue S, Matsuoka O, Kiyosue A, Azuma H, Hayashi N, et al. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. Diabetes Obes Metab. 2013; 15:432-40. [PMID: 23194084]
28. Kashiwagi A, Utsuno A, Kazuta K. ASP1941, a novel, selective SGLT2 inhibitor, was effective and safe in Japanese healthy volunteers and patients with type 2 diabetes mellitus [Abstract]. Diabetes. 2010;59(Suppl 1):75-OR.
29. Kashiwagi A, Takinami Y, Kazuta K, Yoshida S, Utsuno A, Nagase I. Ipragliflozin improved glycaemic control with additional benefits of reductions of body weight and blood pressure in Japanese patients with type 2 diabetes mellitus: BRIGHTEN Study [Abstract]. Diabetologia. 2011;54(Suppl 1):S68-9.
30. List JF, Woo V, Morales E, Tang W, Fiedorek FT. Sodium-glucose cotransport inhibition with dapagliflozin in type 2 diabetes. Diabetes Care. 2009;32: 650-7. [PMID: 19114612]
31. Schwartz SL, Akinlade B, Klasen S, Kowalski D, Zhang W, Wilpshaar W. Safety, pharmacokinetic, and pharmacodynamic profiles of ipragliflozin (ASP1941), a novel and selective inhibitor of sodium-dependent glucose cotransporter 2, in patients with type 2 diabetes mellitus. Diabetes Technol Ther. 2011;13:1219-27. [PMID: 21854192]
32. Seino Y, Sasaki T, Fukatsu A, Samukawa Y, Sakai S, Watanabe T. A novel potent and highly selective renal sodium-glocose co-transporter 2 (SGLT2) inhibitor, TS-071, improves glycaemic control and lowers body weight in Japanese patiens with type 2 diabetes mellitus [Abstract]. Diabetologia. 2011;54(Suppl 1):S68.
33. Seino Y, Sasaki T, Fukatsu A, Samukawa Y, Sakai S, Watanabe T. Luseogliflozin (TS-071), a selective SGLT2 inhibitor, improves glycemic control and lowers body weight in Japanese patients with type 2 diabetes mellitus [Abstract]. Diabetes. 2012;61(Suppl 1):A266-7.
34. Stenlöf K, Cefalu WT, Kim KA, Alba M, Usiskin K, Tong C, et al. Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. Diabetes Obes Metab. 2013;15: 372-82. [PMID: 23279307]
35. AstraZeneca. A 24-week randomised, double-blind, parallel-group, multicentre, placebo-controlled phase III trial to evaluate the efficacy and safety of dapagliflozin as monotherapy in Japanese subjects with type 2 diabetes who have inadequate glycemic control with diet and exercise. Clinical Study Report Synopsis. Wilmington, DE: AstraZeneca; 2012. Accessed at www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/D1692C00006 on 1 April 2013.
36. Bailey CJ, Gross JL, Pieters A, Bastien A, List JF. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial. Lancet. 2010;375: 2223-33. [PMID: 20609968]
37. Bailey CJ, Gross JL, Hennicken D, Iqbal N, Mansfield TA, List JF. Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial. BMC Med. 2013;11:43. [PMID: 23425012]
38. Bode B, Stenlöf K, Sullivan D, Fung A, Usiskin K, Meininger G. Efficacy and safety of canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor (SGLT2), in older subjects with type 2 diabetes mellitus [Abstract]. Diabetologia. 2012;55(Suppl 1):S315.
39. Bolinder J, Ljunggren O, Kullberg J, Johansson L, Wilding J, Langkilde AM, et al. Effects of dapagliflozin on body weight, total fat mass, and regional adipose tissue distribution in patients with type 2 diabetes mellitus with inadequate glycemic control on metformin. J Clin Endocrinol Metab. 2012;97:1020-31. [PMID: 22238392]
40. Ljunggren Ö, Bolinder J, Johansson L, Wilding J, Langkilde AM, Sjöström CD, et al. Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin. Diabetes Obes Metab. 2012;14:990-9. [PMID: 22651373]
41. Bolinder J, Ljunggren O, Johansson L. Dapagliflozin produces long-term reductions in body weight, waist circumference and total fat mass in patients with type 2 diabetes inadequately controlled on metformin [Abstract]. Diabetologia. 2012;55(Suppl 1):S308.
42. Cefalu WT, Leiter LA, Debruin TW, Gausenilsson I, Sugg J, Parikh SJ. Dapagliflozin treatment for type 2 diabetes mellitus patients with comorbid cardiovascular disease and hypertension [Abstract]. Diabetes. 2012;61(Suppl 1): A271.
43. Cefalu TW, Leiter LA, Niskanen L, Xie J, Millington D, Canovatchel W, et al. Efficacy and safety of canagliflozin, a sodium glucose co-transporter 2 inhibitor, compared with glimepiride in patients with type 2 diabetes on background metformin [Abstract]. Diabetes. 2012;61(Suppl 1A):LB10.
44. Devineni D, Morrow L, Hompesch M, Skee D, Vandebosch A, Murphy J, et al. Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin. Diabetes Obes Metab. 2012;14: 539-45. [PMID: 22226086]
45. Dobbins RL, O'Connor-Semmes R, Kapur A, Kapitza C, Golor G, Mikoshiba I, et al. Remogliflozin etabonate, a selective inhibitor of the sodiumdependent transporter 2 reduces serum glucose in type 2 diabetes mellitus patients. Diabetes Obes Metab. 2012;14:15-22. [PMID: 21733056]
46. Goto K, Kashiwagi A, Kazuta K, Yoshida S, Ueyama E, Utsuno A. Ipragliflozin reduces A1C and body weight in type 2 diabetes patients who have inadequate glycemic control on metformin alone: ILLUMINATE study [Abstract]. Diabetes. 2012;61(Suppl 1):A269.
47. Heise T, Seewaldt-Becker E, Macha S, Hantel S, Pinnetti S, Seman L, et al. Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes. Diabetes Obes Metab. 2013;15:613-21. [PMID: 23356556]
48. Henry RR, Murray AV, Marmolejo MH, Hennicken D, Ptaszynska A, List JF. Dapagliflozin, metformin XR, or both: initial pharmacotherapy for type 2 diabetes, a randomised controlled trial. Int J Clin Pract. 2012;66:446-56. [PMID: 22413962]
49. Jabbour S, Hardy E, Sugg J, Parikh S. Dapagliflozin as add-on therapy to sitagliptin with or without metformin: a randomized, double-blind, placebocontrolled study [Abstract]. Diabetes. 2012;61(Suppl 1):A275-6.
50. Kadowaki T, Ikeda S, Takano Y, Cynshi O, Christ AD, Boerlin V, et al. Tofogliflozin, a novel and selective SGLT2 inhibitor improves glycemic control and lowers body weight in patients with type 2 diabetes mellitus inadequately controlled on stable metformin or diet and exercise alone [Abstract]. Diabetes. 2012;61(Suppl 1):A22.
51. Kashiwagi A, Shiga T, Akiyama N. Ipragliflozin reduced HbA1c and body weight in Japanese type 2 diabetes patients who have inadequate glyceamic control on sulfonylurea or pioglitazone alone [Abstract]. Diabetologia. 2012; 55(Suppl 1):S302-3.
52. Kohan DE, Fioretto P, List J, Tang W. Efficacy and safety of dapagliflozin in patients with type 2 diabetes and moderate renal impairment. J Am Soc Nephrol. 2011;22(Suppl):232A-3A.
53. Komoroski B, Vachharajani N, Feng Y, Li L, Kornhauser D, Pfister M. Dapagliflozin, a novel, selective SGLT2 inhibitor, improved glycemic control over 2 weeks in patients with type 2 diabetes mellitus. Clin Pharmacol Ther. 2009;85:513-9. [PMID: 19129749]
54. Leiter LA, Cefalu WT, Debruin TW, Gausenilsson I, Sugg J, Parikh SJ. Efficacy and safety of dapagliflozin for type 2 diabetes mellitus patients with a history of cardiovascular disease [Abstract]. Diabetes. 2012;61(Suppl 1):A287.
55. Matthews DR, Fulcher G, Perkovic V, DeZeeuw D, Mahaffey KW, Rosenstock J, et al. Efficacy and safety of canagliflozin (CANA), an inhibitor of sodium glucose co-transporter 2 (SGLT2), added-on to insulin therapy -/- oral agents in type 2 diabetes [Abstract]. Diabetologia. 2012;55(Suppl 1):S314-5.
56. Mudaliar S, Henry RR, Boden G, Smith S, Chalamandaris AG, Iqbal N, et al. Changes in insulin sensitivity as measured by glucose disposal rate and acute insulin secretion with the sodium glucose co-transporter 2 inhibitor dapagliflozin [Abstract]. Diabetologia. 2011;54(Suppl 1):S349.
57. Nauck MA, Del Prato S, Meier JJ, Durán-García S, Rohwedder K, Elze M, et al. Dapagliflozin versus glipizide as add-on therapy in patients with type 2 diabetes who have inadequate glycemic control with metformin: a randomized, 52-week, double-blind, active-controlled noninferiority trial. Diabetes Care. 2011;34:2015-22. [PMID: 21816980]
58. Del Prato S, Nauck MA, Rohwedder K, Theuerkauf A, Langkilde A, Parikh S. Long-term efficacy and safety of add-on dapagliflozin vs add-on glipizidein patients with type 2 diabetes mellitus inadequately controlled with metformin: 2-year results [Abstract]. Diabetologia. 2011;54(Suppl 1):S348.
59. Nucci G, Amin NB, Wang X, Lee DS, Rusnak JM. The sodium glucose co-transporter-2 (SGLT2) inhibitor, PF04971729, provides multi-faceted improvements in diabetic patients inadequately controlled on metformin [Abstract]. Diabetologia. 2011;54(Suppl 1):S347.
60. Rosenstock J, Jelaska A, Seman LJ, Pinnetti S, Hantel S, Woerle HJ. Efficacy and safety of BI 10773, a new sodium glucose cotransporter-2 (SGLT-2) inhibitor, in type 2 diabetes patients inadequately controlled on metformin [Abstract]. Diabetes. 2011;60(Suppl 1):A271.
61. Rosenstock J, Vico M, Wei L, Salsali A, List JF. Effects of dapagliflozin, an SGLT2 inhibitor, on HbA(1c), body weight, and hypoglycemia risk in patients with type 2 diabetes inadequately controlled on pioglitazone monotherapy. Diabetes Care. 2012;35:1473-8. [PMID: 22446170]
62. Rosenstock J, Aggarwal N, Polidori D, Zhao Y, Arbit D, Usiskin K, et al; Canagliflozin DIA 2001 Study Group. Dose-ranging effects of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to metformin in subjects with type 2 diabetes. Diabetes Care. 2012;35:1232-8. [PMID: 22492586]
63. Schernthaner G, Gross JL, Rosenstock J, Guarisco M, Fu M, Yee J, et al. Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. Diabetes Care. 2013. [PMID: 23564919]
64. Strojek K, Yoon KH, Hruba V, Elze M, Langkilde AM, Parikh S. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebocontrolled trial. Diabetes Obes Metab. 2011;13:928-38. [PMID: 21672123]
65. Strojek K, Hruba V, Elze M, Langkilde A, Parikh S. Efficacy and safety of dapagliflozin as an add-on to glimepiride in T2DM inadequately controlled with glimepiride alone over 48 weeks. Presented at International Diabetes Federation 21st World Diabetes Congress, Dubai, United Arab Emirates, 4-8 December 2011.
66. Wilding JP, Norwood P, T'joen C, Bastien A, List JF, Fiedorek FT. A study of dapagliflozin in patients with type 2 diabetes receiving high doses of insulin plus insulin sensitizers: applicability of a novel insulin-independent treatment. Diabetes Care. 2009;32:1656-62. [PMID: 19528367]
67. Wilding JP, Woo V, Soler NG, Pahor A, Sugg J, Rohwedder K, et al; Dapagliflozin 006 Study Group. Long-term efficacy of dapagliflozin in patients with type 2 diabetes mellitus receiving high doses of insulin: a randomized trial. Ann Intern Med. 2012;156:405-15. [PMID: 22431673]
68. Wilding JP, Woo VC, Rohwedder K, Sugg JE, Parikh SJ. Long-term effectiveness of dapagliflozin over 104 weeks in patients with type 2 diabetes poorly controlled with insulin [Abstract]. Diabetes. 2012;61(Suppl 1):A267-8.
69. Wilding J, Mathieu C, Vercruysse F, Usiskin K, Deng L, Canovatchel W. Canagliflozin (CANA), a sodium glucose co-transporter 2 inhibitor, improves glycemic control and reduces body weight in subjects with type 2 diabetes (T2D) inadequately controlled with metformin (MET) and sulfonylurea (SU) [Abstract]. Diabetes. 2012;61(Suppl 1):A262.
70. Wilding JP, Ferrannini E, Fonseca VA, Wilpshaar W, Dhanjal P, Houzer A. Efficacy and safety of ipragliflozin in patients with type 2 diabetes inadequately controlled on metformin: a dose-finding study. Diabetes Obes Metab. 2013;15: 403-9. [PMID: 23163880]
71. Yale JF, Bakris G, Cariou B, Yue D, David-Neto E, Xi L, et al. Efficacy and safety of canagliflozin in subjects with type 2 diabetes and chronic kidney disease. Diabetes Obes Metab. 2013;15:463-73. [PMID: 23464594]
72. AstraZeneca. A 16-week, multicentre, randomised, double-blind, placebocontrolled phase III study to evaluate the safety and efficacy of dapagliflozin 2.5 mg bid, 5 mg bid and 10 mg qd versus placebo in patients with type 2 diabetes who are inadequately controlled on metformin-IR monotherapy. Clinical Study Report Synopsis. Wilmington, DE: AstraZeneca; 2012. Accessed at www.astrazenecaclinicaltrials.com/_mshost800325/content/clinical-trials/resources/pdf/D1691C00003 on 1 April 2013.
73. Drawing inferences from incomplete data. In: Panel of Handling Missing Data in Clinical Trials, National Research Council, eds. The Prevention and Treatment of Missing Data in Clinical Trials. Washington, DC: National Academies Pr; 2010:65-9.
74. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol. 2010;63:e1-37. [PMID: 20346624]
75. Lundh A, Sismondo S, Lexchin J, Busuioc OA, Bero L. Industry sponsor ship and research outcome. Cochrane Database Syst Rev. 2012;12: MR000033. [PMID: 23235689]
76. Bourgeois FT, Murthy S, Mandl KD. Outcome reporting among drug trials registered in ClinicalTrials.gov. Ann Intern Med. 2010;153:158-66. [PMID: 20679560]
77. Pub. L. No. 110-85, 121 Stat 823.
78. Missing trial data-briefing notes. AllTrials.net. Accessed at www.alltrials.net /wp-content/uploads/2013/01/Missing-trials-briefing-note.pdf on 27 January 2013.
79. Godlee F. Goodbye PubMed, hello raw data [Letter]. BMJ. 2011;342:d212.